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T-cell/histiocyte-rich large B-cell lymphoma is a rare aggressivelymphoma showing histopathological overlap with nodular lym-phocyte-predominant Hodgkin lymphoma. Despite differences in
tumor microenvironment and clinical behavior, the tumor cells of both
entities show remarkable similarities, suggesting that both lymphomas
might represent a spectrum of the same disease. To address this issue,
we investigated whether these entities share mutations. Ultra-deep tar-
geted resequencing of six typical and 11 histopathological variants of
nodular lymphocyte-predominant Hodgkin lymphoma, and nine cases
of T-cell/histiocyte-rich large B-cell lymphoma revealed that genes recur-
rently mutated in nodular lymphocyte-predominant Hodgkin lym-
phoma are affected by mutations at similar frequencies in T-cell/histio-
cyte-rich large B-cell lymphoma. The most recurrently mutated genes
were JUNB, DUSP2, SGK1, SOCS1 and CREBBP, which harbored muta-
tions more frequently in T-cell/histiocyte-rich large B-cell lymphoma and
the histopathological variants of nodular lymphocyte-predominant
Hodgkin lymphoma than in its typical form. Mutations in JUNB,
DUSP2, SGK1 and SOCS1 were highly enriched for somatic hypermu-
tation hotspot sites, suggesting an important role of aberrant somatic
hypermutation in the generation of these somatic mutations and thus in
the pathogenesis of both lymphoma entities. Mutations in JUNB are
generally rarely observed in malignant lymphomas and thus are relative-
ly specific for nodular lymphocyte-predominant Hodgkin lymphoma
and T-cell/histiocyte-rich large B-cell lymphoma at such high frequencies
(5/17 and 5/9 cases with JUNBmutations, respectively). Taken together,
the findings of the present study further support a close relationship
between T-cell/histiocyte-rich large B-cell lymphoma and nodular lym-
phocyte-predominant Hodgkin lymphoma by showing that they share
highly recurrent genetic lesions.
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ABSTRACT
Introduction
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
is a rare subtype of diffuse large B-cell lymphoma
(DLBCL) characterized by a low fraction of tumor B cells
and a cellular background rich in T cells and histiocytes. It
has been classified as a separate entity of mature B-cell
lymphoma since the fourth edition of the World Health
Organization (WHO) classification of lymphoid neo-
plasms.1,2 Although it has a more aggressive clinical behav-
ior and distinct microenvironmental composition,3,4
THRLBCL shares several clinical and pathological features
with nodular lymphocyte-predominant Hodgkin lym-
phoma (NLPHL), a rare subtype of Hodgkin lymphoma.
The similarities include a predominance of middle-aged
male patients5 and a minority of tumor cells derived from
germinal center B cells in an abundant microenviron-
ment.6,7 Furthermore, a high similarity of gene expression
signatures4,8 and genomic copy number changes in the
microdissected tumor cells of NLPHL and THRLBCL were
found.9 According to Fan et al.,10 NLPHL can be subdivided
into six different histopathological patterns, which include
two typical nodular growth patterns (A and B) and four
histopathological variants (C-F). The NLPHL variant E,
also called THRLBCL-like variant, shows particularly
marked similarities with THRLBCL and can only be dis-
tinguished from de novo THRLBCL by the presence of typ-
ical NLPHL remnants in the same lymph node or in anoth-
er lymph node simultaneously sampled. In general,
histopathological NLPHL variants are associated with an
advanced clinical stage and an increased relapse rate.10,11
Data on somatic gene mutations of the tumor cells of
THRLBCL are still lacking. Hence, we aimed to elucidate
the relationship of THRLBCL and NLPHL through a com-
parison of recurrently mutated genes to obtain a more
comprehensive understanding of the pathogenesis of
THRLBCL. 
Methods
Cases 
Cases were collected based on the availability of frozen tissue
at the Dr. Senckenberg Institute of Pathology, Frankfurt am Main,
Germany; the Department of Pathology University Hospitals,
K.U. Leuven, Belgium; the Unit of Lymphoid Malignancies, San
Raffaele Scientific Institute, Milan, Italy; Tampere University
Hospital and University of Tampere, Tampere, Finland; and the
Department of Pathology and Laboratory Medicine and the
Centre for Lymphoid Cancer, British Columbia Cancer Agency,
Vancouver, Canada. The local ethics committees approved the
study, and written informed consent from the donors was
obtained in accordance with the Declaration of Helsinki. All cases
were reviewed on a multi-head microscope by expert
hematopathologists (RG, SH, MLH, and TT). Only cases meeting
the diagnostic criteria of the current WHO classification for
NLPHL and THRLBCL1,2 were included in the study. Coexisting
NLPHL was not found in any of the THRLBCL cases. For correla-
tive analysis, NLPHL cases were classified according to Fan et al.10
For this purpose, the major pattern present in the frozen sample
was considered. In all cases, the initial biopsies before treatment
were analyzed. All cases also presented a typical immunopheno-
type of the tumor cells (CD20+, BCL6+, OCT2+, CD30–, CD15–,
LMP1–). Information on the patients is provided in Table 1. 
Ultra-deep targeted resequencing and identification of
somatic variants
Extraction of genomic DNA from frozen tissue of cases of
THRLBCL and NLPHL, ultra-deep targeted resequencing after
bait-based enrichment by a custom Haloplex kit (Agilent, Santa
Clara, CA, USA) and processing of sequencing reads were carried
out as described previously.12 All 62 genes used for the ultra-deep
targeted resequencing were selected based on mutated genes from
a previous study of two clonally related composite lymphomas
consisting of NLPHL and DLBCL (Online Supplementary Table S1).12
Some of these selected genes were already confirmed to be mutat-
ed in primary NLPHL without transformation into DLBCL.12 The
mean coverage of the 26 cases ranged between 3500 and 8500x
(Online Supplementary Table S2). Non-synonymous single
nucleotide variants (SNVs) were filtered for allele frequencies
based on the expected tumor cell content (0.1-10%), and the pres-
ence and somatic origin of selected variants were confirmed in a
semi-nested polymerase chain reaction (PCR) approach followed
by Sanger sequencing of the PCR products, as indicated in Online
Supplementary Table S3. Details on validation of mutations using
microdissected tumor cells and analysis of the somatic hypermu-
tation (SHM) features of SNVs are provided in the Online
Supplementary Methods section.
Laser microdissection and Immunohistochemistry
Frozen sections (5 - 10 mm) of lymph nodes from lymphoma
patients were mounted on membrane-covered slides (PALM,
Zeiss, Bernried, Germany), then air-dried and fixed in acetone.
Sections were stained with a mouse monoclonal anti-CD20 anti-
body (clone L26, Dako, Glostrup, Denmark) in 1:200 dilution for
1 h at room temperature. Binding of the primary antibody was
visualized with the aid of the Super SensitiveTM Link-Label IHC
Detection System (BioGenex, Fremont, CA, USA), and counter-
staining with hematoxylin was performed. For PCR analysis, 20
single tumor cells and non-tumor cells were isolated using the
PALM laser capture microdissection technique (PALM
MicroBeam, Zeiss, Bernried, Germany) and collected in 20 µL PCR
buffer without MgCl2 (Expand High Fidelity, Roche, Grenzach,
Germany) supplemented with 0.1% Triton X-100.
The immunohistochemical staining for activation-induced cyti-
dine deaminase (AICDA) was performed on an independent series
of 15 typical and 11 variant NLPHL as well as 12 THRLBCL with
formalin-fixed paraffin-embedded tissue as previously described.13
The anti-AICDA antibody (clone EK2 5G9, Cell Signaling,
Danvers, MA, USA) was applied in a dilution of 1:100.  
Results 
T-cell/histiocyte-rich large B-cell lymphoma 
shares recurrently mutated genes with nodular 
lymphocyte-predominant Hodgkin lymphoma 
Ultra-deep targeted resequencing of the coding exons of
62 genes (Online Supplementary Table S1), which were
found to be mutated in NLPHL in a previous study,12 was
performed in the following three groups: THRLBCL (n=9);
typical NLPHL, patterns A/B (n=6); and histopathological
NLPHL variants, patterns C/D/E (n=11), yielding a total
number of 26 cases. The patients’ characteristics are given
in Table 1. The coding exons of selected genes were ana-
lyzed for non-synonymous SNVs in order to identify
mutations with a potential functional effect. 
Of the 62 NLPHL-related genes, 48 (77%) were somati-
cally mutated in at least one of the 26 cases (Online
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Supplementary Table S3). A total of 33 genes (53%) were
recurrently affected by mutations in at least two cases
(Figure 1A). Specifically in THRLBCL, 31 genes (50%)
were mutated, and 13 of these showed recurrent muta-
tions in at least two cases, indicating a considerable muta-
tional overlap between THRLBCL and NLPHL. The genes
with the highest overall mutation frequency (≥20% of all
26 cases) were JUNB, DUSP2, SGK1, SOCS1, CREBBP,
FN1 and TRRAP (Figure 1A). Mutation frequencies in
JUNB, SGK1, CREBBP and TRRAP were higher, albeit not
significantly so, in both THRLBCL and the NLPHL vari-
ants C/D/E than in typical NLPHL A/B (Figure 1A).
The median number of mutated genes per case was
comparable between typical NLPHL (median 3.5; range, 2-
13), histopathological NLPHL variants C/D/E (median 5.0;
range, 1-11) and THRLBCL (median 4.0; range, 2-20)
(Figure 1B). However, the median number of SNVs per
case was slightly increased in THRLBCL (median 12;
range, 2-30) when compared with that in typical NLPHL
(median 7; range, 2-14) and NLPHL variants C/D/E (medi-
an 8; range, 1-20) (Figure 1C). Notably, the number of
SNVs per case was specifically increased in the four genes
JUNB, DUSP2, SGK1 and SOCS1 (1-5 SNVs/case) when
compared to CREBBP, FN1 and TRRAP (1-2 SNVs/case),
particularly in regard to the shorter coding sequence of the
first four genes (<1.3 kb versus >7.3 kb) (Figure 1D). The
higher number of SNVs per case found in THRLBCL was,
therefore, related to the higher number of SNVs in these
four genes.
SOCS1 was the only gene in which mutations occurred
significantly more frequently in THRLBCL than in typical
NLPHL A/B (4/9 cases versus 0/6 cases, respectively;
P=0.010, χ2-test) and in NLPHL in general (4/9 cases versus
3/17 cases, respectively; P=0.035, χ2-test). 
Furthermore, the number of SNVs per case was signifi-
cantly increased in SOCS1 in THRLBCL (median 5.0;
range, 3-6) when compared with that in histopathological
NLPHL variants C/D/E (median 1.5; range, 1-2; P=0.048,
Mann-Whitney test). JUNBwas the gene with the highest
number of nonsense mutations, which were present in
both NLPHL (2/15 mutations) and THRLBCL (2/12 muta-
tions).
The genes with the highest mutation frequency 
are targets of aberrant somatic hypermutation
Regarding the distribution of mutations in the seven
most recurrently mutated genes, SNVs were generally dis-
tributed throughout the coding sequence with no differ-
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Table 1. Clinical information on nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma patients.
Case                   Former                      Diagnosis                               Fan pattern#          Estimated tumor           Gender         Age                     Stage
number         case number*                                                                                                cell content                     
1                                                                       THRLBCL                                                                                     15%                                M                  20                              IVB
2                                                                       THRLBCL                                                                                      5%                                 M                  47                              IVB
3                                                                       THRLBCL                                                                                     10%                                F                  50                              IVB
4                                                                       THRLBCL                                                                                     15%                                M                  40                              IVB
5                                                                       THRLBCL                                                                                     10%                                M                  50                              n.a.
6                                                                       THRLBCL                                                                                      1%                                 F                  89                              IVA
7                                                                       THRLBCL                                                                                     10%                                M                  27                              IVA
8                                                                       THRLBCL                                                                                      3%                                 M                  31                              IVB
9                                                                       THRLBCL                                                                                      5%                                 F                  75                              IIIA
10                                                                Variant NLPHL                                    pattern E                             1%                                 M                  59                              IVB
11                                                                Variant NLPHL                                    pattern E                             1%                                 M                  46                              IVA
12                                                                Variant NLPHL                                    pattern E                             1%                                 F                  85                             IIIB
13                                                                Variant NLPHL                                    pattern E                             3%                                 M                  40                              IVB
14                                                                Variant NLPHL                                    pattern E                             5%                                 M                  23                              IIIA
15                                                                Variant NLPHL                                    pattern E                             3%                                 M                  46                              IVA
16                                  6                             Typical NLPHL                                    pattern A                             3%                                 M                  10                              IIA
17                                  7                             Typical NLPHL                                    pattern A                             1%                                 M                  72                              n.a.
18                                   8                             Typical NLPHL                                    pattern A                             1%                                 M                  64                              n.a.
19                                   9                             Typical NLPHL                                    pattern A                             3%                                 M                  13                               IA
20                                 10                            Typical NLPHL                                    pattern A                             1%                                 M                  52                              n.a.
21                                 11                            Typical NLPHL                                    pattern B                             3%                                 F                  53                              n.a.
22                                   5                     Variant NLPHL , part of                            pattern D                            3%                                 M                  35                              n.a.
                                                                composite lymphoma
23                                                                  Variant NLPHL                                    pattern C                             1%                                 M                  64                              n.a.
24                                 12                            Variant NLPHL                                    pattern C                             3%                                 M                  15                              IIA
25                                 13                            Variant NLPHL                                    pattern D                            3%                                 M                  31                               IA
26                                 17                            Variant NLPHL                                    pattern D                            3%                                 M                  75                              n.a.
* These cases were included in a previous study of nodular lymphocyte-predominant Hodgkin lymphoma.12 # Histopathological patterns were determined according to Fan
et al.10 THRLBCL:T-cell/histiocyte-rich large B-cell lymphoma; NLPHL: nodular lymphocyte-predominant Hodgkin lymphoma; n.a.: Information on Ann Arbor stage was not
available.
ence in the mutational distribution between the three
groups of lymphoma (Figure 2). Protein domains with
functional relevance were affected by mutations, e.g. the
SH2 domain of the negative regulator of JAK-STAT signal-
ing SOCS1, the catalytic domain of the protein kinase
SGK1 and the histone acetyltransferase domain of the
chromatin modifier CREBBP, suggesting that mutations in
these genes result in an alteration of the protein function.
In the three relatively small genes (<2.5 kb) JUNB, DUSP2
and SOCS1, SNVs clustered to specific regions in the cod-
ing sequence with an enrichment to the first 150 bp down-
stream of the start codon in JUNB, to exon 2 in DUSP2
and to the first 80 bp of the coding sequence in SOCS1. In
CREBBP, FN1 and TRRAP, which were the three larger
genes (>75 kb), mutations tended to be diffusely scattered
and localized further downstream of the transcriptional
start site. Given the fact of ongoing SHM in NLPHL and
THRLBCL,6,7 as well as aberrant activity of the SHM
machinery in these entities,14 we explored whether muta-
tions in the most recurrently mutated genes were caused
by aberrant SHM. Criteria of SHM activity were investi-
gated, as previously described in other reports.14–17
Mutations in the genes JUNB, DUSP2, SGK1 and SOCS1
were highly enriched in SHM hotspot sites (Figure 3A) and
also met other SHM criteria in most SNVs (Figure 3B,C).
Mutations in CREBBP, FN1 and TRRAP occasionally
occurred at C:G sites and showed a predominance of tran-
sitions over transversions (Figure 3B,C). However, they
were clearly located outside the SHM hotspot motifs
WRCY/RGYW (Figure 3A). In line with these results of an
active SHM machinery and consistent with previous
data,13,18 expression of AICDA could be demonstrated in
the tumor cells of typical and histopathological NLPHL
variants (10/15 and 3/11 cases, respectively) (Figure 3D) as
well as THRLBCL (10/12 cases) (Figure 3E) in an inde-
pendent case series. 
Discussion
In the present study, we performed ultra-deep targeted
resequencing of a set of genes that had been previously
identified to be mutated in two cases of composite lym-
phoma of NLPHL with transformation into DLBCL.12 Four
of these target genes, namely JUNB, DUSP2, SGK1 and
SOCS1, were also found to be mutated in primary NLPHL
cases without transformation. Since the relationship of
NLPHL and THRLBCL has been long-discussed, we aimed
to determine whether these four genes, among others, are
also mutated in THRLBCL. Here, we confirm that muta-
tions in these genes also occur at comparable frequencies
in THRLBCL. 
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Figure 1. Genes recurrently affected by mutations and their mutational load in nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large
B-cell lymphoma. (A) Frequencies of recurrently mutated genes (≥2 cases) in six cases of NLPHL A/B (blue), 11 cases of NLPHL C/D/E (green) and nine cases of
THRLBCL (red) sorted by overall recurrence. (B) Mutated genes per case in NLPHL A/B, NLPHL C/D/E and THRLBCL. (C) Number of SNVs per case in NLPHL A/B,
NLPHL C/D/E and THRLBCL. (D) Scatter plot of SNVs per case and kbp of CCDS in the seven most recurrently mutated genes in NLPHL A/B, NLPHL C/D/E and THRL-
BCL. In (B-D), horizontal lines correspond to medians; P-values by Kruskal-Wallis test are indicated in the case of statistical significance. *P<0.05, **P<0.01,
***P<0.001. NLPHL: nodular lymphocyte-predominant Hodgkin lymphoma; THRLBCL: T-cell/histiocyte-rich large B-cell lymphoma; SNVs: single nucleotide variants;
CCDS: Consensus coding sequence. 
A
B C D
B. Schuhmacher et al.
334 haematologica | 2019; 104(2)
Figure 2. Mutation patterns in the most recurrently mutated genes in nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell
lymphoma. Schematic overview of the mutational distribution in the most recurrently mutated genes. For each gene missense (triangles), stop gain (spheres) and
splice site (squares) mutations are mapped to coding exons (top) and protein domains (bottom). Mutations are color-coded according to the occurrence in the groups
(blue: NLPHL A/B; green: NLPHL C/D/E; red: THRLBCL). Amino acid positions of protein domains are adopted from the Uniprot database (www.uniprot.org) and refer
to the canonical sequences (JUNB: P17275, DUSP2: Q05923, SGK1: O00141, SOCS1: O15524, CREBBP: Q92793, FN1: P02751, TRRAP: Q9Y4A5). bZIP: basic
leucine zipper motif; DsPc: dual specific phosphatase, catalytic domain; Pkinase: protein kinase domain; AGC-kinase C: AGC-kinase C-terminal domain; Rhod: rho-
danese; SH2: Src homology 2 domain; KIR: kinase inhibitory region; CH1/2/3: cysteine/hystidine-rich region; KIX: kinase inducible domain; BROMO: bromodomain;
HAT: histone acetyltransferase domain; Q: poly glutamine stretch; FN: fibronectin; TP53: tumor suppressor p53 binding site; FAT: FRAP-ATM-TRRAP domain; FATC: FAT
C-terminal; PI3K/PI4K: phosphatidylinositol 3-kinase/ phosphatidylinositol 4-kinase domain; NLPHL: nodular lymphocyte-predominant Hodgkin lymphoma; THRLBCL:
T-cell/histiocyte-rich large B-cell lymphoma.
SGK1 and SOCS1 are frequently mutated in germinal
center B-cell (GCB)-derived lymphomas such as follicular
lymphoma and GCB-type DLBCL.18–21 DUSP2 is less fre-
quently mutated in malignant lymphomas; however,
DUSP2mutations have been described in DLBCL,15,22,23 pri-
mary mediastinal B-cell lymphoma24 and chronic lympho-
cytic leukemia.25 In contrast, to date, JUNB has been
reported, to our knowledge, to be relatively specifically
mutated in NLPHL.12 The total percentage of samples of
hematopoietic and lymphoid neoplasms with mutations
in JUNB in the COSMIC database
(https://cancer.sanger.ac.uk/cosmic) is 0.09% (3 of 3516 sam-
ples tested). Two of these cases had non-synonymous
mutations: one DLBCL and one lymphoid neoplasm not
otherwise specified (COSMIC ID COSS2121012). The
third case, a cutaneous T-cell lymphoma of mycosis fun-
goides type,26 presented a synonymous JUNBmutation. In
the whole exome sequencing study on classical Hodgkin
lymphoma by Tiacci et al.27, only one of 34 cases presented
a non-synonymous JUNB mutation. Therefore, the high
frequency of non-synonymous JUNBmutations, including
a relatively frequent occurrence of JUNB nonsense muta-
tions in both NLPHL and THRLBCL, is a hallmark of these
lymphoma entities. 
Mutations in the four genes JUNB, DUSP2, SGK1 and
SOCS1 were more frequent in THRLBCL and the
histopathological NLPHL variants than in typical NLPHL.
Since we performed ultra-deep targeted resequencing of
whole tissue DNA and allowed allele frequencies of muta-
tions to range within the expected tumor cell content (0.1-
10%), this approach might more sensitively identify sub-
clonal variants in THRLBCL than in NLPHL due to the
slightly higher tumor cell content in THRLBCL compared
to NLPHL (median 10% versus 3%). However, the tumor
cell content did not differ significantly between
histopathological NLPHL variants and typical NLPHL (3%
versus 2%, respectively) and thus does not explain the
higher number of mutations in histopathological NLPHL
variants than in typical NLPHL.
SOCS1 is a known target of aberrant SHM,18 and SHM
of immunoglobulin genes is known to be ongoing in the
tumor cells of NLPHL and THRLBCL.6,7,14 The mutation
patterns of JUNB, SGK1, DUSP2 and SOCS1 observed in
the tumor cells of NLPHL and THRLBCL suggest that
mutations in these four genes are most likely the result of
aberrant SHM, which is likely contributing importantly to
the development of these lymphomas. The genes DUSP2
and SGK1 were previously identified as potential targets
of aberrant SHM in GCB-type DLBCL,15 but are less fre-
quently mutated in GCB-type DLBCL than in NLPHL and
THRLBCL. SHM activity is reported to start closely down-
stream from the transcriptional start site extending up to 2
kb into the gene,28 which is in line with an enrichment of
SNVs in SHM hotspot motifs in the three relatively small
genes JUNB, DUSP2 and SOCS1 (<2.5 kb). The more fre-
quent occurrence of SNVs in SHM hotspot sites in THRL-
BCL and histopathological NLPHL variants might be relat-
ed to a longer and/or stronger exposure of the tumor cells
to the SHM machinery. Aberrant activity of the SHM
machinery may be caused by loss of target specificity and
JUNB, DUSP2, SGK1 and SOCS1 mutations in THRLBCL
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Figure 3. Characteristics of somatic mutations and activation-induced cytidine deaminase expression in nodular lymphocyte-predominant Hodgkin lymphoma and
T-cell/histiocyte-rich large B-cell lymphoma. (A) Analysis of distribution of mutations to SHM hotspot motifs. (B) Ratio of mutations at C:G sites to A:T sites. (C) Ratio
of transition to transversion mutations. In (A-C) synonymous SNVs were considered in addition to non-synonymous SNVs. Asterisks denote statistical significance.
*P<0.05, **P<0.01, ***P<0.001. P-values by χ2 test. (D) Expression of AICDA in the LP cells of NLPHL (400x magnification). (E) Expression of AICDA in the tumor
cells of THRLBCL (400x magnification). Tumor cells are highlighted by arrows. AICDA: activation-induced cytidine deaminase; NLPHL: nodular lymphocyte-predomi-
nant Hodgkin lymphoma; THRLBCL: T-cell/histiocyte-rich large B-cell lymphoma; SHM: somatic hypermutation; SNVs: single nucleotide variants.
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lead to insertion of mutations into genomic regions show-
ing active transcription and a favorable epigenetic environ-
ment.15,29,30 This might also contribute to the more aggres-
sive clinical behavior of these entities if a high rate of aber-
rant SHM affects further target genes that were not pro-
filed here. 
According to our data, SOCS1, previously shown to be
mutated in NLPHL,12,31 was mutated in both histopatho-
logical NLPHL variants and THRLBCL. SOCS1 was not
mutated in the typical NLPHL cases of this study, as
observed previously.12 This is likely related to the low
number of typical NLPHL cases investigated. On the
other hand, one may speculate that SOCS1 may act as a
potential driver gene indicating disease progression and
may thus represent a progression driver. However, the
histopathological growth patterns of the NLPHL cases
investigated were not considered in the study by Mottok
et al.31 Despite the fact that typical NLPHL represents the
majority of NLPHL cases, in our experience most frozen
NLPHL samples are acquired from histopathological
NLPHL variants. One reason for this may be because the
patients with histopathological NLPHL variants present
with more advanced disease and are more likely to pres-
ent in a specialized medical center where frozen tissue
can be preserved. A potential role of SOCS1 as a driver
towards disease progression is further supported by pre-
vious reports, in which SOCS1 missense mutations were
found to be related to a more aggressive clinical behavior
in a cohort of DLBCL cases treated with CHOP-like regi-
mens.32 The prognostic impact of SOCS1 mutations
should therefore be investigated in a larger cohort of
NLPHL. Moreover, as the ultra-deep targeted sequencing
approach used here is not very reliable in the identifica-
tion of structural variants, these were not considered
here. Given that a high number of SOCS1 aberrations
have been reported to be insertions/deletions31,32 we,
therefore, likely underestimate the frequency of SOCS1
mutations. 
Mutations in the acetyltransferase CREBBPwere usually
not a result of aberrant SHM. They frequently affected the
KIX domain that mediates binding to transcription
factors,33 the HAT domain that performs histone acetyl-
transferase activity and the C-terminal Q-rich domain,
which is part of a transactivation domain,33 consistent
with the functional consequences reported for DLBCL and
follicular lymphoma.34 Notably, two mutations in the HAT
domain of CREBBP detected in DLBCL (nonsense R1341X
and R1360X)34 also occurred at the same residue in a
patient with NLPHL variant pattern E (R1341X) and a
patient with THRLBCL (R1360P), suggesting that the HAT
domain is under inactivating pressure in these GCB-cell
derived malignancies. Thus, in addition to aberrant SHM,
further transforming events are likely required for the
development of NLPHL and THRLBCL.
Since the gene panel applied in the present study was
based on genes previously identified in composite lym-
phomas of NLPHL and DLBCL, we were not in a position
to identify novel genes that are recurrently mutated in
THRLBCL but not or only rarely in NLPHL. This is a clear
limitation of our study. Thus, genome-wide mutation
studies are warranted to comprehensively determine the
mutational landscape of THRLBCL. Nevertheless, the fact
that the most frequently mutated genes in NLPHL are also
recurrently mutated in THRLBCL makes a strong point
regarding the close relationship of these malignancies,
which had been proposed in earlier studies based on
histopathological features, related gene expression pro-
files, and similar genomic imbalances.4,8,9 Perhaps de novo
THRLBCL could principally represent a transformation
from NLPHL, and thus share key mutations that were
acquired in the earlier NLPHL lymphomagenesis.
Considering the clinical presentation of the patients, one
could speculate that typical and histopathological NLPHL
variants have a similar relationship to THRLBCL, as is
observed in follicular lymphoma grade 1/2 to 3a and trans-
formation into DLBCL. 
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